Inhalte im Video:
Interview von:
Produziert von:
29. Sep. 2019Priv.-Doz. Dr. Aysegül Ilhan-Mutlu

ESMO 2019: “Ich habe noch nie höhere Ansprechraten gesehen”

Priv.-Doz. Dr. Aysegül Ilhan-Mutlu, Universitätsklinik für Innere Medizin I, Wien, fasst die Studien-Highlights zu Karzinomen des oberen Gastrointestinaltrakts zusammen.

Themen waren dabei u.a. die Unterschiede in der optimalen Behandlung asiatischer und europäischer Patienten, positive Outcomes der KEYNOTE-062 in der Subgruppe mit hoher Mikrosatelliteninstabilität (MSI) und überraschende Ansprechraten bei der kombinierten Behandlung mit Immun- und Antikörpertherapie.

Abstracts, die im Interview diskutiert wurden:

  • Kang YK et al. Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. #LBA43
  • Kang YK et al. Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY). #LBA41
  • Ji J et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial). #LBA42
  • Shitara K et al. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062. #LBA44
  • Chen J et al. 760P – Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181
  • Janjigian Y et al. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. #817P
Quelle

ESMO Congress 2019